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                                                     ABSTRACT 
HIV and TB are major public health problem undermining socio-economic development. HIV is the 
main reason for failure to meet tuberculosis control target. Considering this fact, a descriptive study 
was conducted in Addis Ababa City Administration. This study aimed to assess uptake of VCT, the 
current prevalence of HIV and uptake of ART and CPT among registered TB patients in public 
DOTS clinic of Addis Ababa City Administration, and to identify potential barriers and opportunities 
in the collaboration between national TB and HIV control programmes. 
 
Data were collected from TB register logbook and TB/HIV quarterly report format of 24 DOTS 
clinic, found in Public Health Centres. All registered TB patients over the period of one year were 
included in the study.  Literature, annual plans and reports were reviewed to identify barriers and 
opportunities to the collaborative TB and HIV control programmes.  
 
During one year period a total of 8272 patients were registered in the DOTS clinics, 7036 (85%) of 
them were tested for HIV/AIDS. The overall prevalence of HIV was 23.3%, almost equal proportion 
of males and females found to be HIV positive and the prevalence was high in age group between25-
34.  Pulmonary tuberculosis patients had higher HIV prevalence, 24.7% compared to extra 
pulmonary, which had 22%. VCT uptake among registered TB patients was on the way of the global 
target, 85%; however, the uptake of ART and CPT were unsatisfactory. While sound policies and 
political commitment were identified as an opportunity, lack of well organized HIV surveillance 
system among tuberculosis patients was the major barrier for collaborative TB/HIV programme in the 
city administration. It was concluded that HIV prevalence among TB patients was moderate and 
uptake of ART and CPT were unsatisfactory. Finally, further quantitative and qualitative studies that 
investigate TB/HIV collaborative programme should be needed. 
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1. INTRODUCTION 
1.1 Background 
The rapid growth of the human immune deficiency virus (HIV) epidemic is the main reason for 
failure to meet tuberculosis (TB) control targets, particularly in countries which have high HIV 
prevalence. The HIV pandemic is a forceful contributor to the incidence of tuberculosis. Globally, 
from the year 1990 to 2004, TB incidence increased from 125 cases to 142 cases per 100,000 
populations, primarily because of the HIV pandemic [21]. In some sub Saharan African Countries, 
like Tanzania, Malawi, Zambia and Burundi, which had strong TB control programmes, the HIV 
epidemic has led to a 100- 300% increase in TB notification [22]. Approximately, greater than 30%, 
and 60-80% of TB cases are HIV sero positive in the more northern and the southern part of the 
African region, respectively [23]. In 2006, in 112 countries about 700,000 people with TB were 
tested for HIV, on average half of them found to be HIV positive [1].  From year 2002-2006, 50% of 
HIV positive people with TB were accounted in 11 sub Saharan Africa countries, including Ethiopia 
[2].  
 
Death rates among HIV infected TB patients are much higher than non-HIV infected patients. Among 
a million of TB deaths a quarter is HIV associated, with most of them in the African region [24]. In 
this regard Brazil and South Africa were typical examples. In Brazil the case fatality rates for TB was 
13%, where as in South Africa 27%, this large difference was due to the difference in HIV infection 
rate [25]. In HIV infected smear-positive pulmonary TB patient’s case fatality rates can be of the 
order of 20-30% and in smear-negative pulmonary TB or disseminated extra-pulmonary TB can be 
higher, because there may be difficulties in making accurate and timely diagnoses and patients in 
these latter categories are often more immunosuppressed [26].  Worldwide, in 2009 about 1.68 
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million deaths occurred due to TB, including 0.38 million patients infected with HIV. Of these deaths 
the African region accounted for 20% [2, 4].  
 
 TB is the most common opportunistic infection and, one of the major causes of morbidity and 
mortality among people living with HIV. And also it is a very common presentation of HIV/AIDS, 
and in most cases, it is the earliest manifestation in high HIV and TB prevalence settings. In the range 
of 20 to 45% of AIDS patients had TB in high HIV prevalence countries of the African region [22]. 
According to WHO, globally, 11.5 million HIV infected people are co infected with mycobacterium 
tuberculosis. Of these, 24 % are found in South East Asia, Latin America and the Caribbean but 70% 
of co infected people are found in the most badly affected countries of the African region [1]. In sub 
Saharan Africa TB contributes between 30-40% of deaths in HIV positive adults [23].  
 
Human Immunodeficiency Virus and Mycobacterium Tuberculosis are among the leading causes of 
morbidity and mortality in Ethiopia. Among the list of 22 TB high burden countries Ethiopia ranks 
8
th
 in the world and 3
rd
 in Africa, next to Nigeria and South Africa, and the 10
th
 highly affected 
country by the HIV/AIDS pandemic in the world [2, 3, and 14]. Like other sub Saharan African 
countries Ethiopia is badly hit by the HIV/TB co- epidemic. From July 2005 to June 2006 routine 
data collected from 44 sites of the country showed that 41% of the TB patients were HIV positive. 
However, official data for HIV/TB co-infection are lacking, some unpublished internal reports at 
FMoH indicate that the prevalence of HIV among TB patients is rapidly increasing. A few previous 
studies conducted in the country have shown that HIV/TB co infection is higher in urban setting 
including the capital city, Addis Ababa [6, 7]. This rapidly growing dual epidemic problem requires 
well integrated TB/HIV activities; however, too often NTP and NACP are not working together.  
This study is, therefore undertaken to determine the current prevalence of HIV among TB patients, 
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the five year’s trends, and to identify the potential barriers and opportunities for the collaborative TB 
and HIV programmes. 
 
1.2 Global Situation of Tuberculosis  
Globally, TB is one of the major public health problems undermining development. 
Epidemiologically, TB is disease of poverty; however, many industrialised countries are also hit by 
TB, including Scandinavia and the United States of America. Previously the proportion of infected 
people with mycobacterium tuberculosis was similar both in industrialized and developing nations. 
Around one third of the world’s population, more than 2 billion peoples, are or have been infected 
with mycobacterium tuberculosis [2, 11]. The three diseases of poverty, TB, Malaria, and HIV/AIDS 
kill 6 million people every year; of those nearly 2 million deaths are due to TB. Even if TB is a 
curable disease, it kills 5000 people every day [24]. Socio economic status, age and geography are 
highly associated with infection of mycobacterium tuberculosis. To support this association, in 
developing countries 75% of infected individuals are less than 50 years old while 80% of those in 
industrialized countries are aged 50 or more in  the year1990 [11].   
 
In this, Millennium Developmental Goals (MDGs) and the stop TB Partnership’s reference year, 
1990, 7.6 million (95%) and 400,000 (5%) new cases of TB were found in developing and 
industrialized countries respectively [11] and also TB was the 7
th
 leading cause of disability adjusted 
life years (DALYs) and the 7
th
 leading cause of death in the world. The largest number of cases 
where found in the western pacific regions of WHO 2.6 million. The African region accounted for 1.4 
million. In that year, TB was the largest cause of death from a single pathogen, worldwide, leading to 
2.9 million deaths. of these, 660,000 occurred in the African region [27].  
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After two decades, TB is being continues to be a cause of morbidity and mortality, despite the global 
scale-up of the stop TB strategies to control tuberculosis. It caused an estimated 9.4 million incident 
cases, 14 million prevalent cases, and 1.68 million deaths, and also a notified cases of 5,800,000 in 
the year 2009. 85% of cases were found in South-East Asia, African and Western Pacific regions of 
WHO. In addition to this   approximately 250,000 MDR-TB cases were included in the estimated TB 
cases [2, 11]. Currently, Africa accounted for more than 25% of the global tuberculosis burden, 
although it has only 11% of the world’s population.  Today the African region accounts for an 
estimated 2.4 million tuberculosis cases, and 540,000 tuberculosis deaths, the leading number of 
annual deaths in the world [28]. Particularly, Southern and Horn of Africa owing to endemic poverty, 
weak health systems, poor tuberculosis control strategies, and generalised HIV epidemic, has resulted 
in MDR and X-MDR TB, which radically raises treatment costs, duration of treatment and lower 
chance of treatment success. Out of the 22 TB high burden countries in the world 9 of them are in the 
African region [29]. 
 
1.3 Ethiopian Situation of Tuberculosis 
Approximately 80% of the estimated number of new TB cases accounted in 22 high TB burden 
countries, including Ethiopia. More than half a century ago tuberculosis has been recognized as a 
major public health problem in Ethiopia. From infectious disease TB is one of the leading causes of 
death in the country. According to FMoH, TB was the leading cause of morbidity, the second cause 
of death, and the third cause of hospital admission (next to deliveries and malaria), in the year 2007 
[12]. According to the Global Report 2010 by WHO, with an estimated incidence of all forms of TB 
of 300 new Cases/100,000 pop/year, Prevalence of all forms of TB is 480/100,000 population and 
12% HIV prevalence in incident TB cases, Ethiopia is one of the high TB burden countries in the 
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world [2]. Currently, due to HIV and MDR TB, TB is the major public health threat in the world; this 
is also the case in Ethiopia.  
 
Despite 6.9 million cases diagnosed, notified and treated not only for smear positive TB, but also for 
all forms of TB, and 90% treatment success rate of smear positive TB are the current indicators of the 
stop TB strategy [41]. It is questionable whether Ethiopia can meet the target by 2015. For the last 
decade national routine surveillance of TB data have shown that every year more than 100,000 all 
forms of TB cases were detected in the country. From 1 July 2000 to 30 June 2010, 392,319 smear 
positive TB and 430 274 extra pulmonary TB (EPTB) cases were reported. Within this decade the 
case notification of all forms of TB increased from 89,642 to-149 508, the case detection rate (CDR) 
of all forms of TB moved from 43% to 50%, and the treatment success rate (TSR) increased from 
76% to 84% [3]. These increments were not significant comparing with the international target.  
 
Addis Ababa City Administration annually contributed on average 13,500 [13,000-14,000] new TB 
cases of the approximated 100,000 annual national TB cases, over the last three years. The city has a 
case detection and treatment success rate of 63% and 80%, respectively, comparing with the stop TB 
target of case detection 70% and treatment success rate 85%, it is lower. This success rate mainly 
registered through DOTS, and some privates and NGOs clinics. Of the estimated 5000, MDR TB 
cases in the country Addis Ababa city have 400 registered MDR TB cases. Currently St. Peter 
General Specialized Hospital is providing treatment for 180 MDR TB patients [43].   
 
1.4 Global and Regional Burden of HIV/AIDS  
HIV/AIDS is one of the major public health challenges undermining socio-economic development in 
the world, and low-income countries, in particular. Globally, there were an estimated 33.3 million 
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people living with HIV in 2009. In the same year 2.6 million people became infected with HIV and 
1.8 million people died of AIDS related causes. Young people aged 15-25 account for 45% of new 
cases of HIV infection worldwide. Above 50% of all people living with HIV globally are women. An 
estimated 370, 000 and 260,000 children were newly infected with HIV through mother-to-child 
transfer and died from AIDS related illness in the year 2009, respectively. Furthermore, 5.2 million 
people were under antiretroviral therapy in low and middle income countries and US$ 15.9 billion 
was spent on HIV/AIDS [14]. Since the beginning of the HIV epidemic more than 25 million people 
have died, globally [28].   
 
 The impact of HIV and AIDS in the African continent has been massive. Annually, it reduces GDP 
growth by an estimated 0.5 and 2.6, respectively in the continent [28]. Unlike Asia, the HIV/AIDS 
epidemic level is generalised in this resource constraint continent. In 2007, 64% of people living with 
HIV/AIDS were in Africa, which accounts for 11% of world’s population [15]. Sub Saharan Africa is 
the most heavily affected region by the HIV pandemic. According to UNAIDS (2010) report an 
estimated 1.8 million people living in sub Saharan Africa became newly infected with HIV in 2009, 
bringing the total number of people living with HIV to 22.5 million, which accounted 68% of HIV 
infections worldwide. In the same year an estimated 2.3 million children living with HIV were in Sub 
Saharan Africa, which accounted for 90% of the world’s children living with HIV [14]. Due to 
HIV/AIDS more than 14.1 million children in the region estimated to have lost one or both parents in 
2008 [16]. In 2009 an estimated 1.3 million AIDS related deaths occurred in the region, which 
accounted for 72% of the worlds AIDS related deaths. The proportion of women living with HIV in 
Sub Saharan Africa is higher than men. Although the number of adults and children living with HIV 
is high in sub Saharan Africa, antiretroviral therapy coverage in the region is low. An estimated 63% 
of people eligible for ART were unable to access life saving medicines in 2009; this was the highest 
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next to Eastern Europe and central Asia region. Ethiopia, Nigeria, South Africa, Zambia and 
Zimbabwe accounted the largest epidemic in the region [14]. 
 
1.5 The Burden of HIV/AIDS in Ethiopia  
Ethiopia is one amongst other countries heavily hit by the HIV pandemic. In 2004 there were 
approximately 1.5 million people living with HIV of which 817,000 women and 96,000 were 
children under 15 year, which makes it the fifth nation in the world with the largest population of 
HIV infected persons [17].  From July 2009 to June 2010, approximately 1.1 million people were 
living with HIV and 44,750 AIDS related deaths occurred. In the same year, 796,009 mothers visited 
health facilities, out of which 653,065 pregnant women received an HIV test and, 13,257 were found 
to be HIV positive, and about 14,140 babies were expected to be born as HIV positive. There are also 
more than 855,720 orphans due to HIV/AIDS out of the estimated total 5.4 million orphans in the 
country. Furthermore, 268,934 HIV/AIDS patients have been ever started on anti retro viral treatment 
in the country [4]. 
 
HIV prevalence in Ethiopia is quite different in the urban and rural settings. The spread of HIV/AIDS 
started and was initially localized in major urban areas located along major roads and commercial 
routes of the country [17]. In 2010, the national HIV prevalence was 2.4%, where as the urban 
prevalence was 7.7%. Addis Ababa city administration is the most highly affected cities of the 
country. There were 22,214 new HIV infections and 5,948 annual deaths in the year 2009. In 2010, 
210,306 people were living with HIV and 70,097 HIV positive peoples were in need of ART, in the 
city. The estimated HIV prevalence of the city was 9.2%, above 10 times higher than the rural 
prevalence, which is 0.9% [20]. 
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1.6 The Impact of HIV on TB
6
 
Among many risk factors for the progression of TB infection to active disease HIV is the most potent 
one. Risk of developing TB is 10 times higher in individuals infected with HIV compared with not 
infected with HIV. HIV increases relapses and the likelihood of re-infections of TB. It also increases 
the rate of progression of recent or latent tuberculosis. On the life time HIV positive individuals have 
50% lifetime risk of developing TB compared with 5-10%, -of those who have negative HIV status 
[6]. 
In countries where HIV/TB is common like Sub Saharan African countries, health services struggle 
to cope with the large and rising number of TB. In East and southern Africa the HIV/AIDS epidemics 
have increased the tuberculosis case load by five or more times [30]. In such type of countries 
HIV/AIDS has a number of impacts on prevention and control of TB. HIV increases the number of 
TB patients and suspects. The impact includes the following [6]: 
 infrastructural and Human capital problem in the health sector 
 Risk of health facility based TB infection  
 Services for case detection and treatment 
 Illness and death in health care workers owing to HIV related TB and high turnover of health 
professionals due to fear of the risk consequently reducing staff numbers, and increasing the 
workload of remaining staff. Which in turn compromise quality of service 
 Low staff morale due to conditions of service, anxiety and powerlessness 
  The risk of getting MDR & XDR-TB among health care workers could be high 
 Over diagnosis of sputum smear-negative PTB, because of difficulties in diagnosis 
 Due to excess laboratory workload, under diagnosis of sputum smear-positive PTB  
 Insufficient monitoring of anti-TB chemotherapy; 
 Very low cure rates in advanced immunosupressed individuals 
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 Morbidity during treatment is high  
 Due to other opportunistic infections, high mortality rates during treatment 
 High default rates because of adverse drug reactions; 
 High side effects and high rates of drug-drug interactions  
 High rates of TB relapse 
 
1.7 Rationale of the Study  
HIV and TB prevention and control programs share mutual concerns. TB prevention and treatment 
should be priority concern for HIV prevention and control program; HIV prevention, care and 
treatment should be a priority for TB control program [6]. Integrated HIV/TB activities are essential 
to tackle the burden of TB among people living with HIV and the burden of HIV among TB patients 
and should be priority for both HIV and TB control programmes; especially in countries were TB and 
HIV prevalence are high like Ethiopia.  
 
HIV is an important risk factor for development of TB by destroying the immune defence mechanism 
of the body. Furthermore, HIV further aggravates TB in countries like Ethiopia were socioeconomic 
status is fragile, and subsequent change of attitude and behaviour are low. In addition to this HIV 
changes the frequency, distribution and determinants of TB. 
 
The findings of HIV/TB as well as TB/HIV co-infection assessment can lead to concerted effort for 
the design of further collaborative co-infection programming, implementation and monitoring and 
evaluation. Therefore, it is important to analyze the prevalence of HIV among TB patients. This study 
will explore the prevalence of HIV among TB patients in public DOTS clinic of Addis Ababa. In 
addition, identifying the opportunities and barriers to TB and HIV/AIDS interaction enables how to 
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promote effective interaction in the future. The end outcome of this study is probably essential to 
increase the commitment to provide integrated HIV/AIDS care, support and treatment to HIV 
positive TB patients.  
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2. LITERATURE REVIEW 
2.1 HIV-TB Co-Infection Prevalence Studies  
Several health institutions based and few community based HIV-TB co-infection prevalence studies 
were conducted in the world, including sub Saharan Africa. In 2006, the sero prevalence of HIV 
among 6,533 registered TB patients in USA was 12% [31]. In 2010 an institution based study 
conducted in Guangxi, China showed that the prevalence of HIV among pulmonary tuberculosis 
patients was higher than in the general population [32]. A recent study conducted at DOTS centres of 
rural Haryana, India revealed that HIV sero prevalence was 1.3 times higher in male TB patients than 
female patients [33]. 
 
Different sub Saharan African countries were reported greater than 40% of HIV sero prevalence rates 
among TB patients.  In Kenya and Uganda, 60% and 30% of newly diagnosed tuberculosis patient 
were HIV positive, respectively [34]. In 2005 another study conducted in Kampala, Uganda revealed 
42% HIV sero prevalence among TB patients [35]. Twenty five percent of TB patients were found 
HIV sero positive in a recent institution based study from Nigeria, and the prevalence of   HIV was 
higher in females, and in the age group 38-47 [36]. 
 
Few studies have been conducted regarding the prevalence of HIV among TB patients in Ethiopia; 
most of them are health institutions based cross- sectional. In the year 2003 the study conducted in 
Arsi, Oromiya regional state revealed that the sero prevalence of HIV among registered TB patients 
was 37.2%. Almost equal proportions of females and males found to be HIV sero positive, 36.3% and 
37.9%, respectively. HIV prevalence was significantly higher in subjects in the 20-39 years age group 
[34]. A similar study in Shashemena, in the same region, indicated that 44.4% of tuberculosis patients 
were HIV positive in 1994 [39]. Another study done in Harar, Eastern Ethiopia in 1997 showed 22% 
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of sero positive among smear positive  and 20.4% of sero positive in culture positive TB patients 
[42]. In 2000 a study conducted in Addis Ababa revealed 45.3% of sero prevalence among 236 AFB 
confirmed TB patients [7]. 
 
2.2 Diagnosis and Treatment of HIV Associated TB 
Diagnosis of tuberculosis is more difficult in HIV infected TB patients comparing with non infected 
individuals. The HIV epidemic has power to change the clinical feature (course) of the disease 
tuberculosis. In addition, HIV reduces smear positive TB cases of both pulmonary and extra 
pulmonary TB [37]. Still now, many TB high burden countries are using the 125 years old sputum 
smear microscopy test method of TB detection. Such method has a number of drawbacks. Low 
sensitivity in HIV positive individuals and unable to detect rifampicin drug resistance which is a 
reliable indicator for MDR TB are major drawbacks. Xpert MTB/RIF is the newly promising fully 
automated rapid TB diagnostic test. It should be and may be used as the initial diagnostic test in 
individuals suspected of MDR-TB or HIV/TB in high burden countries and a follow-on test to 
microscopy in settings where MDR-TB and or HIV is of lesser concern, respectively [38].  
 
Principally, there is no unique treatment for HIV positive TB patients; it is the same to non co-
infected individuals. Occurrence of immune reconstitution, overlapping toxic effects, drug 
interactions, and regimen length and schedule of administration of anti tuberculosis drugs, timing and 
drug combinations of antiretroviral drugs are exceptional issues associated with co-infected 
individuals. Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol are the drugs of choice for the 
treatment of tuberculosis, irrespective of HIV status. According to WHO, TB treatment, parallel with 
co-trimoxazole and immediately followed by anti retroviral therapy within 8 weeks is the first 
priority for HIV positive TB patients. Co-trimoxazole has a number of impacts in HIV positive TB 
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patients; it prevents Pneumocystis jirovecii, malaria, different bacterial infections and reduces death. 
ART should be recommended for all HIV positive TB patients, regardless of CD4 cell count in order 
to improve their survival. Furthermore, ART reduces TB rate by 90% and 60% at the individual and 
population levels, respectively [37]. 
 
2.3 Global Tuberculosis Control Strategies 
The six principal components of the global stop TB strategies are:  
1. Pursue high-quality DOTS expansion and Enhancement;  
2. Address TB/HIV and MDR-TB and other special challenges;  
3. Contribute to health system strengthening,  
4. Engage all care providers;  
5. Empower people with TB, and communities;  
6. Enable and promote research.  Among those DOTS is the backbone of the strategy, which was 
launched in 1994. Worldwide, more than 49 million patients had been treated in DOTS programmes 
from 1995 to 2009; of them more than 41 million had been treated successfully. It is the basic for the 
other five principles of stop TB strategy [41, 13].  
The following five points are required to further strengthen DOTS strategy [13]. 
Political commitment with improved and persistent financing at all levels, from the higher to the 
smallest unit of government administration system; 
Case detection through quality-assured bacteriology test of sputum smear microscopy, culture and 
drug susceptibility test; 
Standardized treatment by following the WHO guidelines, including supervision, patient support and 
access to treatment; 
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An effective drug supply and management system; essential anti TB drugs should be available at 
relevant health facilities without payment; 
Monitoring and evaluation system, and impact measurement; recording and reporting of all TB 
patient data and cohort outcomes are crucial. 
 
Addressing collaborative TB/HIV, MDR and other challenges are the second principal component of 
the stop TB strategy. HIV not only increases the rate of recurrent TB, but also promotes the 
progression of recent and latent mycobacterium tuberculosis infection to active TB disease. The HIV 
epidemic has caused a significant decrease in the percentage of cases of smear- positive pulmonary 
and extra pulmonary TB. MDR-TB, which partly is caused by the widespread misuse of second-line 
anti-TB drug; and the absence of new effective drugs to treat TB, is a treat to the stop TB strategy. 
Thus screening of all HIV patients to TB and the vice versa and effective prevention and control of 
MDR-TB should be integrated in the national TB control programmes, especially in highly TB 
prevalent countries.  
 
The third principal component of the stop TB strategy is; contribute to health system strengthening. 
Health system consists of; health work force, finance, information, management, vaccine and medical 
products and service delivery that could be disease specific, such as maternal and child health, 
HIV/AIDS programmes, lung health and  NTPs. Thus TB control strategies should be integrated, 
share and adopt innovations with other parts of the broader health care system. 
 
DOTS and STOP TB strategy for TB control in Ethiopia was adopted since 1990s. DOT facility 
assessment was conducted in the country in February 2011, the result of the assessment indicates that, 
2,367 health centres out of 2,480 health centres (95%) and 110 hospitals out 119 hospitals (92%) are 
implementing DOTS-based services. In addition, 2,100 health posts across the country; 15% of total 
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existing health posts provide TB treatment follow up under the DOTS strategy. Currently, the Health 
Facility coverage is 95% whereas the geographic coverage of DOTS reaches 100% [3]. The other 
five components of the stop TB strategy are also implemented in the country together with other parts 
of the health system.  
 
2.4 Collaborative TB and HIV/AIDS Activities  
The co-existence of the HIV pandemic accelerates the global burden of TB and TB has a significant 
impact on the life expectance of PLWHA.  
Strong collaborative programme between the national TB and HIV/AIDS programmes key to address 
the two diseases in one person. Successful integration of National TB and HIV/AIDS programmes is 
an entry point to the collaborative TB/HIV or HIV/TB activities. Thus to reduce the burden of TB 
among people living with HIV/AID (PLWHA) and the burden of HIV/AIDS among TB patients 
WHO recommends  12 essential activities under the umbrella of three categories. These are [13, 40, 
and 41]: 
A) Establishing the mechanism for collaboration between the programmes, NTP and NACP  
1. Form a joint national TB and HIV coordinating body that includes TB and HIV patient 
support groups from the top to the bottom level of health services; 
2. Prepare and execution of a joint national plan between NTP and NACP, including budgeting; 
3. Conduct surveillance of HIV among TB patient and the vice versa depend on the prevalence 
of HIV in the country; 
4. Effective monitoring and evaluation mechanism for the collaborative TB/HIV activities; 
B) Reduce the burden of HIV among TB patients 
5. Provide counselling and testing of HIV for All TB patients: Without the HIV epidemic level 
of the countries, the world health organisation recommends HIV counselling and testing for 
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all patients with or without confirmed TB but who present with sign and symptoms of 
tuberculosis [37]. According to the global stop TB plan by 2010 and 2015, 85% and 100% TB 
patients should be tested for HIV, respectively; 
6. Provision of HIV/AIDS prevention services; ensure TB patients know how to prevent HIV, 
including methods to reduce transmission of HIV and TB; 
7. Provision of co-trimoxazole preventive therapy (CPT) for HIV positive TB patients, 
according to the global stop TB plan to provide 95% and 100% CPT to HIV positive TB 
patient by 2010 and 2015, respectively; 
8. Provision of ART to HIV positive TB patient, all HIV positive TB patients should put on 
ART regardless of their CD4 status; 
9. Provision of care and support to HIV positive TB patients; 
C)  Reduce the burden of TB in people live with HIV/AIDS 
10. Intensified TB case finding, 100% screening of PLWHA for TB, by 2015 
11. Provision of isoniazid preventive therapy (IPT), all HIV positive peoples without active TB 
should put under IPT, by 2015 
12. Ensuring TB infection control in health care and congregate settings, HIV positive peoples are 
at risk of developing TB, thus infection control at health facilities is critical to protect 
PLWHA from getting TB.  
 
2.5 Surveillance of HIV among TB Patients 
5
  
As the HIV pandemic continues to fuel the global tuberculosis epidemic, it is more significant to 
conduct surveillance of HIV among TB patients and it is a sensitive indicator for the spreading of 
HIV in to the general population. Surveillance of the prevalence of HIV among TB patients will 
provide information on the level of the dual epidemics, TB and HIV and useful to give ART, CPT, 
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IPT, and general HIV/AIDS care and support. According to the World Health Organisation there are 
3 methods of surveillance of HIV prevalence among TB patients: data from the routine testing of 
tuberculosis patients for HIV, sentinel surveillance and special surveys. These are depending on: 
previous surveillance system, a countries state of the underlying HIV prevalence; the situation of 
tuberculosis, and ART implementation status [5].  
1. Data from the routine testing of tuberculosis patients for HIV :- when routine HIV testing data among 
TB patients available, this method of surveillance should be used at generalised, and concentrated 
HIV epidemic level and it is highly recommended in countries where the level of HIV is generalised, 
like sub Saharan African countries. Despite that this method has given contradictory results, in poor 
countries due to poor testing procedures and inadequate quality control, it provides the opportunity to 
receive collaborative prevention and care programmes for co-infected patients [5].  
2. Sentinel surveillance: - is used when routine HIV testing data among TB patient is lacking, in 
countries with a generalised, concentrated or low HIV epidemic level. Such method is advantageous 
for analysis of trends and to provide point HIV prevalence among TB patients estimates.  Owing to 
well established HIV sentinel system this method is the simplest and the cheapest surveillance 
system. Such method might be biased if the sentinel sites were not selected through probability-based 
sampling methods [5]. 
3. Special or periodic survey: - the recommended surveillance method for countries where the 
prevalence is previously unknown and classified HIV epidemic levels are missing. This is also a 
typical method in resource constraint with under- developed surveillance systems and in settings 
where the general HIV prevalence may be high but other methods of surveillance are not practical. 
Even though such method is expensive and time consuming, with excellent sampling method may 
provide reliable estimate of HIV prevalence among TB patients. Like sentinel surveillance this 
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method is used as a calibration in countries where data from routine HIV testing among TB patients 
used for surveillance purposes [5].   
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3. OBJECTIVES OF THE STUDY 
3.1 General Objective 
To assess the prevalence of HIV infection among TB patients in public DOTS clinic and the 
barriers and opportunities in the collaborative between TB and HIV/AIDS programmes in 
Addis Ababa city administration, Ethiopia. 
 
3.2 Specific Objectives 
 To assess  the sero- prevalence of HIV infection, and uptake of ART and CPT among 
public DOTS clients in Addis Ababa  
 To assess uptake of  Voluntary Counselling and Testing, among registered TB patients  
 To identify potential barriers and opportunities in the collaborative between the 
national TB and HIV programmes in Addis Ababa   
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4. METHODOLOGY 
4.1 Study Setting 
Ethiopia is located in the African continent, which is one the country of Sub Saharan Africa. African 
oldest and independent country, it is the tenth largest country in Africa covering 1,104,300 square 
kilometres and is the major constitute of the land mass known as the Horn of Africa. Ethiopia is 
estimated to have a population of nearly 80 million with a rapid growth rate of 3.2% per year; making 
it the second populated country in Africa, next to Nigeria .Approximately 15% of the population is 
urban dwellers while the majority (85%) live in the rural areas. Life expectancy at birth is quite low 
at 58.38 years for females and 53.28 years for males while the infant mortality rate is high at 79 per 
1,000 live births. The median age of the population is 16.8 years, implying that nearly half of the 
population is aged over 15 years [10]. 
 
Ethiopia is a federal democratic republic composed of nine regional states: Oromia, Amhara, 
Southern Nations, Nationalities, and Peoples, Tigray, Somali, Afar, Benishangul Gumuze, Gambella 
and Harari and two city administrations council of Addis Ababa and Dire Dawa, which have the 
power to raise their own revenues. The regional states and city administrations are sub divided in to 
817 administrative districts. The 817 districts are further divided in to about 16,253 Kebeles; the 
smallest administrative unit in the governance [10].TB/HIV co-infection activities at federal and 
regional level are co-ordinated by both the health ministry and bureaus, and national and regional 
HIV/AIDS prevention and control offices.  
 
The study area Addis Ababa administrative region is the capital city of Ethiopia covering an area of 
540 sq. km, and with a total population of about 2.9 Million. 5046 peoples per square kilo meter, 
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more of slum and overcrowded. The Administrative region has 10 sub cities and 106 woredas 
(districts) [8]. There are many different ethnic groups with different living standards. According to 
Addis Ababa health bureau report of 2010, there were 49 hospitals of which 13 were government 
owned, 5 NGOs and 31 are private, 27 public health centres, and 130 public health stations, 700 
different levels private clinics are found in Addis Ababa city Administrative region [9]. Of them 29 
public, and 29 private and NGOs health facilities are currently providing DOTS service. 
 
4.2 Study Design 
A descriptive study was conducted to assess the prevalence of HIV among TB patients in 24 DOTS 
clinics, which are found within public Health centres of Addis Ababa, Ethiopia.  
 
4.3 Source and Study Population 
The source population is all TB patients in Addis Ababa City Administration, while DOTS clients 
were the study population over the period of one year, from July 2010-June 2011. 
 
4.4 Data Collection 
Secondary data were collected from TB registries, and quarterly TB/HIV reports form of 24 public 
health centres found in 10 sub cities of Addis Ababa City Administration. All DOTS clinic clients 
who were screened for TB and documented in the TB registration logbook were included in the 
study. Annual reports, manuals, guidelines and other literature were reviewed to identify potential 
barriers and opportunities in the collaboration between the TB and HIV/AIDS programmes. The data 
was collected by the principal investigator and one public health specialist from 15July – 31July 2011 
using a separate registration form. After the required data were collected, the analysis was made 
using Excel window 2007. 
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4.5 Study Variables 
Dependent variable: HIV status of TB patients. 
Independent variables: Age, sex, type of TB case and site of TB infection. 
 
4.6 Operational Definitions  
Prevalence: - is given as the proportion of individual in a population having a disease. For example, 
if all Norwegians, 5million, are screened for TB and 250 of them are found to be positive, then the 
prevalence of TB in Norway is 0.005% or 5/100,000 population.  
Surveillance: - is the ongoing systematic collection, analysis and interpretation of data, and provision 
of information for effective responses of a disease. For example, the aim of surveillance of HIV 
among TB patients in health facilities of Addis Ababa, Ethiopia is to analyse, prevent and control 
HIV among TB patients. 
DOTS: - the world health organisation recommended and internationally accepted best strategy for 
TB control.  
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5. RESULTS 
5.1 Description and Sero Status of TB Patients 
During one year period, from July 2010 to June 2011 a total of 8272 tuberculosis patients of all type 
were registered and under treatment in 24 public health centre DOTS clinic of Addis Ababa City 
Administration. Among these 4096 (49.5%) were females and 4176 (50.5%) were males, making the 
female to male ratio nearly 1:1. All of the TB patients agreed and attended the voluntary counselling 
services, which are providing in the same compound as the DOTS clinic. Of the 8272 registered TB 
patients 7036 agreed to be tested for HIV. All age group patients registered in the TB register 
logbook were included in the study. The age group of the HIV positive TB patients was varied from 
0-65+ years. 
The overall HIV prevalence among the registered TB patients who were voluntarily tested for HIV 
was found to be 1640 (23.3%). The majority, 575 (35%) of the HIV positive tuberculosis patients 
were in the age group of 25-34, whereas only 16 (almost 1%) were in the age group above 65. 
Concerning HIV sero positivity by sex, 810 (22.75%), of the male was found to be HIV positive, 
while the corresponding figures for females were 830 (23.85%). HIV prevalence was higher in 
patients had pulmonary site of infection, 24.7%. 
Regarding study sites, out of the total study subjects’ Yeka sub city contributed the highest followed 
by Kirkose sub city with 1271 and 1111 registered TB patients over one year period respectively, in 6 
public health centres, 3 each. The lowest numbers of study subjects were found in Lideta sub city, 
which had 317 registered TB patients. The prevalence of HIV sero positives among the registered TB 
patients varied depending on the total number of cases per public health centres being registered. 
According to table 6, the highest proportion was found from Beletshachew and woreda 9 Health 
centres 61 and 70 sero positive out of 171 and 210 registered TB patients respectively. The lowest 
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HIV prevalence rate was found in Addis Ketema and woreda 3 health centres with 9.85 and 10.17% 
sero prevalence out of 702 and 314 study subjects.  
Table 1 HIV Status Distributions of DOTS follow up Patients in 24 Public Health 
Centres in Addis Ababa, from July 2010 to June 2011 
Study Subject=8272  HIV Status  
Tested  n  % 
Positive  1640 23.3% 
Negative  5396 76.7% 
Total  7036 85% 
Not tested 1236 15% 
    
Table 2 Sex Distribution and HIV Status of Registered TB Patients  
TB and HIV status   Male  Female  Total  
Registered TB patients 4176 4096 8272 
HIV tested TB patients 3556 3480 7036 
HIV positive TB patients 810 830 1640 
HIV prevalence among TB patients  22.75% 23.85% 23.3% 
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Table 3 HIV status among TB patients, and age group classification, Addis 
Ababa, from July 2010 to June 2011 
Type of Patients 
Age Group Classification 
0-4 5-14 15-24 25-34 35-44 45-54 55-64 65+ Total 
No TB Patients 60 212 900 2948 2749 1014 328 61 8272 
No HIV+ TB Patients  8 46 188 575 551 195 61 16 1640 
 
Table 4 Site of Infection and HIV Status of TB Patients  
Site of Infection 
HIV Status 
Total 
Positive Negative  Not Tested 
Pulmonary 1013 (24.7%) 3080 605 4698 
Extra pulmonary 543 (22%) 1922 579 3044 
Other 84 (17.6%) 394 52 530 
Total  1640 5396 1236 8272 
 
Table 5 Distribution of sero status and type of TB case in 24 public DOTS Clinic, 
Addis Ababa, from July 2010 to June 2011 
Sero Status 
Study subject= 8272 
Type of TB patient 
New Case Relapse Defaulter Not Specified  Total  
Positive 1298 270 29 43 1640 
Negative 4744 443 78 131 5396 
Not tested 1115 95 10 16 1236 
Total  7157 808 117 190 8272 
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Table 6 Distribution of Registered TB Patients by Sub City and Health Centre, Addis Ababa, 2010/2011  
Serial 
Number 
Name of Sub 
City 
Name of Health Centre 
Sero Status of the Study Subject=8272 
Total =8272 
Positive Negative Not tested 
1 Addis ketema Addis ketema health centre 62 567 73 702 
Woreda 7 health centre 100 238 51 389 
2 Akaki kaliti Akaki health centre 85 228 14 327 
Kaliti health centre 81 189 42 312 
Saries health centre 43 219 0 262 
3 Arada  Arada health centre 92 216 84 392 
Gulele health centre 99 244 90 433 
Kebena health centre 30 102 24 156 
4 Bole  Bole 17 health centre 60 149 41 250 
 Bole 17/20 health centre 49 124 4 177 
5 Gulele  Selam health centre 26 141 104 271 
Shiromeda health centre 93 200 132 425 
6 Kirkose  Kasanchis health centre 107 259 19 385 
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Serial 
Number 
Name of Sub 
City 
Name of Health Centre 
Sero Status of the Study Subject=8272 
Total =8272 
Positive Negative Not tested 
Kirkose health centre 66 302 63 431 
Meshaulekia health centre 20 102 173 295 
7 Kolefe keraniyo Kolfe health centre 87 404 19 510 
Woreda 9 health centre 102 233 86 421 
8 Lideta  Beletishachew health centre 61 110 8 179 
Lideta health centre 30 92 16 138 
9 Nifas Silk Lafeto Woreda 3 health centre 29 256 29 314 
Woreda 9 health centre 70 140 22 232 
10 Yeka  Entoto health centre 50 232 4 286 
Kotebe health centre 137 433 28 598 
Yeka health centre 61 216 110 387 
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 5.2 Uptake of Voluntary Counselling and Testing among the Study Subjects 
For HIV prevention and treatment and to avoid co-infection among TB patients voluntary counselling 
and testing is an essential intervention. In this study, during one year period out of the total 8272 
registered TB patients, 8272 (100%), which was 100% male and 100% female have agreed to 
voluntary counselling for HIV testing. Regarding voluntary tested clients, out of the total 8272 TB 
patients who agreed to voluntary counselling for testing only 85% of them, with almost equal 
proportion of male and female have agreed and tested, and their HIV result recorded in the TB 
register.  The rest 15% they haven’t know their HIV status.  
 
Table 7 Uptake of Voluntary Counselling and Testing among Registered TB 
Patient by Sex 
 
Male Female 
n % n % 
Registered TB Patient 4176 50.5% 4096 49.5% 
Have agreed for VC 4176 100% 4096 100% 
Have agreed for VT 3556 85.5% 3480 84.5% 
 
5.3 Uptake of Antiretroviral Therapy and Cotrimoxazole Preventive Therapy  
Out of the total 1640 sero positive TB patients 859 (52%) and 1309 (80%), were found to be put on 
ART and CPT, respectively.  
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Table 8 Distribution of ART and CPT Treatment among HIV Positive TB 
Patients, Addis Ababa, 2010/2011 
Sex Sero Status Put on ART Put on CPT 
Positive n % n % 
Male 810 427 52.7% 645 79.6% 
Female 830 469 56.5% 727 87.6% 
Total  1640 896 54.6% 1372 83.65% 
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Schematic Diagram of TB/HIV Co-infected Patients 
 
Total Registered TB Patient=8272 
Tested for 
HIV=3480 
 
Not 
Tested=616 
 
Positive=830 
 
Negative=2650 
 
Placed on 
ART=469 (56.5%) 
 
Placed on 
CPT=727 (87.6%) 
 
Male=4171 Female=4096 
Tested for 
HIV=3556 
Not Tested=620 
Positive=810 Negative=2746 
Placed on 
ART=427 
(56.5%) 
Placed on 
CPT=645 
(79.5%) 
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5.4 Collaboration between TB and HIV Programmes  
After the recommendation of WHO to increase collaboration between TB and HIV programmes in 
2004, Ethiopia has worked to increase TB/HIV collaborative activities. Integrated TB/HIV activities 
have been achieved in Ethiopia from federal to district health facility levels. The federal democratic 
republic of Ethiopia’s ministry of health is responsible to include and address the link between TB 
and HIV in the national HIV/AIDS and TB programmes.  And also, it is responsible for developing 
national TB/HIV collaborative policies, guidance, strategic planes, guidelines and manuals for 
implementation of TB/HIV collaborative activities, follow up of implementation, and conducting 
monitoring and evaluation of the collaborative programme [46]. Based on this mandate, since the last 
5 year the ministry has improved performance of the collaborative activities. Since then HIV testing 
among TB patients increased from 16% in 2006 to 45% in 2010, and the sero prevalence of HIV 
among tested registered TB patients decreased from 31% to15%. Screened HIV positive clients for 
TB have increased to 79% in 2009/2010 from 47% in 2006/2007, and the prevalence of active TB 
among registered HIV positive clients was 11% in the year 2009/10 [3]. 
 
Addis Ababa Health Bureau is responsible for adopting the collaborative TB/HIV policies, strategies, 
guidelines, manuals from the ministry [46] and implementation of the detail activities together with 
10 sub city health offices and health facilities those providing the collaborative activities in the city.  
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Table 9 Opportunities and Barriers for Collaborative TB/HIV Activities in Addis Ababa, Ethiopia 
Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
Mechanism 
for 
Collaborative 
NTP and 
NACP 
 Existence of National TB and HIV 
policy that addresses collaborative TB 
/ HIV linkage and reflects 
international policy guidance [12,46] 
 Presence of a TB/HIV coordinating 
body or mechanism and technical 
working group at City health bureau 
level, sub city health office and health 
facility level, which include UN 
agencies, NGOs, and religious 
institutions [47].  
 Existence of integrated and 
harmonized joint the city 
 Absence of clear regular 
system of HIV 
surveillance among TB 
patients [52] 
  All public, private & 
NGO’s health facilities un 
-able to provide integrated 
TB/HIV service [48]  
 Surveillance of HIV 
among TB patient is 
not the government 
priority ( lack of 
ownership), it is 
running by CDC  
 
  Shortage and inequitable 
distribution of resources, 
Huge amount of fund is 
coming from international 
sources, the government 
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Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
administration TB/HIV plan with 
earmarked budget [47] 
 Presence of an integrated city level 
Monitoring and Evaluation system for 
collaborative TB/HIV activities that 
inform annual and five year HSDP 
planning [48]   
 Presence of urban health extension 
worker’s and existence of joint 
,comprehensive and linked  TB/HIV 
information, education and 
communication (IEC) materials  to 
provide health education about the 
link between TB and HIV, and to 
budget for this programme 
is very small, 
Much of the funding is 
allocated to the National 
AIDS control programme 
followed by TB, funding 
for the collaborative 
activity is less,  except the 
global fund [50] 
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Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
create community awareness [49]  
 Presence of continuous TB/HIV  
training for health professionals and 
quarterly TB/HIV reporting system 
[50] 
 Presence of political commitment at 
all level [50] 
 Existence of horizontal health care 
system, NTPs and NACPs 
managerially horizontal [51]   
Reduce the 
burden of TB 
in People live 
with HIV 
 Many public health sector health 
facilities implementing intensified TB 
case finding for those found to be 
HIV positive [48] 
 Lack of modern and 
organised laboratory for 
diagnosis of TB, only a 
century old microscopy is 
 Delay in amending IPT 
eligibility criteria  
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Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
 Availability of IPT for HIV positive 
patients suspected for TB in all public 
health facilities, which provide 
TB/HIV integrated services  
 Availability of TB infection 
prevention guidelines and 
implementing committees at health 
facility level [53] 
 Availability of free or low cost TB 
diagnosis and treatment  services [51]  
available at the public 
health centres [48] 
 Absence of a formal 
referral mechanism 
between HIV counselling 
and testing clinics and TB 
diagnostic and treatment 
services [4] 
 Many VCT centres lack 
TB  diagnosis and 
treatment clinics [48] 
 Absence of one stop 
TB/HIV collaborative 
service at health facility 
level  
 
Reduce the 
burden of 
HIV among 
 All DOTS clinics of government 
health facilities have HIV counselling 
and testing services in the same site 
 Lag of adopting WHO 
guidelines and strategies, 
that addresses HIV among 
Delay in amending CPT and 
ART eligibility criteria ( 
according to WHO all HIV+ 
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Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
TB patients  [48]  
 Availability of CPT for HIV positive 
TB patients in all public health 
facilities, which provide TB/HIV 
integrated services [48] 
 Availability of ART for HIV positive 
TB patients in all public health 
facilities, which provide TB/HIV 
integrated services [48] 
 Provision of material and other 
economic support for sero positive 
TB patients [4] 
 Availability of HIV care and support  
services [4] 
TB patients [54] TB patients are eligible for 
CPT and ART but  this is not 
applied in Ethiopia) 
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Perspectives 
Opportunities and Barriers for Collaborative  NTP and NACP Remarks and Reference 
Opportunities Potential Barriers Remark Reference 
 Accessibility of universally free anti 
retro viral treatment, both in 
governmental and nongovernmental 
health facilities [4] 
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6. DISCUSSION  
Addis Ababa city has long been, and still is, affected by tuberculosis. “Its co-infection with 
the HIV pandemic has been compounded and has further aggravated the situation” [34]. In the 
city, the prevalence of HIV among the general population varies from year to year. This study 
revealed that the overall HIV prevalence among registered tuberculosis patients in all age 
group is 23.3% which is higher than the HIV prevalence in the general population. The result 
of this study is consistent with other studies conducted in sub Saharan Africa, which is 
between 20-60% [44]. However, this prevalence rate is lower compared to other previous 
studies conducted in Southern Ethiopia in 1994, Arsi in Oromiya regional state in 2003, and 
again with another study reported in Addis Ababa, which revealed 44.4% [39], 37.2% [34], 
45.3% [7] sero prevalence among registered TB patients, respectively. This discrepancy 
would be probably attributed to the type of study, the study time and the study area; all the 
above studies were conducted 5 years ago when the HIV prevalence had not levelled off and 
all of them were observational. Thus, this study conducted in public DOTS clinics of the 
biggest city in Ethiopia, a high risk area, would probably give a representative picture of 
tuberculosis and HIV co-infection in the city administration.  
 
Globally, some studies concerning HIV sero prevalence among tuberculosis patients have 
reported highly variable rates. In 2005 the study conducted in Kampala, Uganda revealed 42% 
sero HIV prevalence among registered TB patients [35], and 12% [31], 0.5% [32], and 0.56% 
[33] HIV sero prevalence were found among TB patients in USA, Guangxi, China and 
Haryana, India, respectively.  
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Unlike Asians, Africans have unusual characteristics of HIV/AIDS, which is generalised and 
equal distribution of cases among males and females [15]. Similarly the current study is 
consistent with this finding where HIV prevalence was 22.8% in males and 23.85 in females, 
nearly the same. Tuberculosis can affect everyone in the population, regardless of age groups. 
According to the 2010 report of FHAPCO, HIV/AIDS prevalence was high among the age 
group 15-24 [4]; however, this study revealed that the prevalence of HIV is higher among the 
age group of 25-34 years. This might reflect the age specific HIV prevalence in the 
community.   
 
According to the Stop TB plan 2011- 2015, 100% of the TB patients should be tested for HIV 
by 2015 [41]. The present study found that 3536 (85.5%) male and 3480 (84.5%) female, a 
total of 7036 (85%), were tested for HIV, this finding is not bad relative to 86% found in 
Malawi in the year 2007[45]. Comparing with the stop TB target 100% by 2015, this 
achievement is promising for the city administration to achieve the target in the coming four 
year; however, there is a need to amend national policies for HIV testing among TB patients 
and TB suspects, training should be provided for health professionals.    
 
While the uptake of HIV counselling and testing among TB patients in the city administration 
is promising and on the way to the international target, the extent of anti retro viral therapy 
(ART) among HIV positive TB patients is unsatisfactory. Out of the total 1640 HIV positive 
TB patients 896 (54.6%), 427 (52.7%) male and 469 (56.5%) female where placed on ART 
during one year period, these figures are very far from the Global stop TB 2011-2015 plan, 
which is to enrol 100% HIV positive TB patients on ART. Three years ago 68% of TB 
patients in Malawi and 73% in South Africa were immediately enrolled on ART; and 
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compared to this the current percentage of Addis Ababa is quite low.  HIV sero positive TB 
patients enrolled on cotrimoxazole preventive therapies (CPT) were 1372 (83.65%), 645 
(79.6%) male and 727 (87.6%) female. These percentages are close to 100%, the global stop 
TB targets by 2015 but it is low compared to South Africa, 98% HIV positive TB patients 
were received CPT in 2006 [45] .  
 
Sound policies and political commitments are an entry point to the collaborative TB/HIV 
programmes. In addition, the newly implemented horizontal general health care system is a 
major opportunity to programme collaboration. However, the collaboration needs further 
strengthening, the 2006-20115 the global plan to stop TB almost achieved, 85% of TB 
patients screened for HIV, above 10% of HIV positive TB suspects were put on IPT. But the 
uptakes of ART and CPT among TB patients were under the target, which needs special 
attention by the city administration.   
 
Lacks of well organised HIV surveillance system among TB patients were found to be one of 
the biggest barriers in the collaboration between NTPs and NACPs. In addition, shortage and 
unfair distribution of resources to programmes collaboration were considered as a threat. 
Furthermore, the present study identified others barriers, like absence of one stop TB/HIV 
collaborative services at health facility level, lack of formal referral system between HIV and 
TB clinics, and under capacity laboratory services. These are bottlenecks to further 
strengthening of the collaboration between the programmes. 
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7. Strengths and Limitations of the Study  
7.1 Strengths  
This study has covered 24 (96%) out of 25 of public health centres providing integrated 
TB/HIV services. The data was collected directly from the TB registry and collected by the 
principal investigator and one public health specialist. Moreover all registered TB patients 
during one year period were included in the study. In addition, indicators to identify potential 
barriers and opportunities for collaborative TB/HIV activities were adopted from the WHO 
guidelines. Thus, the findings of the study are reliable and can represent the true figure of 
HIV/TB co-infection in Addis Ababa city. 
 
7.2 Limitations  
Due to the nature of the study, we were unable to identify factors associated with low uptake 
rate of ART and CPT, and other associated factors related to TB/HIV co-infection. 
Furthermore, due to poor TB registry data management system and high turnover of health 
professionals from DOTS clinic, one public health centre and four public hospitals providing 
TB/HIV service were excluded from the study. 
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8. CONCLUSIONS  
 The prevalence of HIV among registered TB patients was moderate  
 Despite many opportunities for TB/HIV collaborative activities, there are some barriers 
 Uptake of Voluntary Counselling and Testing services  among TB patients was promising 
 Uptake of ART and CPT were  low 
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9. RECOMMENDATIONS  
1. To increase the uptake of ART and CPT, HIV treatment guidelines and ART and CPT 
eligibility criteria should be amended 
2. Regular surveillance of HIV among TB patients is needed   
3. Strengthen patient initiated HIV counselling and testing among TB patients  
4. “One stop” TB/HIV service should be launched 
5. Further quantitative and qualitative studies that investigate collaborative TB and HIV 
programmes are needed  
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Annex 1. Data Registration Form  
TB/HIV Data of Public DOTs Clinics of Addis Ababa City, Ethiopia, July/2011 
Name of Sub 
city 
Name of health 
facility 
Number  of 
TB patients 
registered 
for the last 
one year 
Number of 
TB patients 
voluntary 
for HIV 
counselling 
Number of 
TB patients 
tested for 
HIV  
Number of 
TB patients 
tested HIV+ 
Number of 
TB patients 
tested  HIV- 
Number of 
HIV+TB 
patients put 
on ART 
Number of 
HIV+TB 
patients put 
on CPT 
M F M  F  M F M F M F M F M F 
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Age Distribution of TB &HIV+TB Patients 
Age (yrs) 0-4 5-14 15-24 25-34 35-44 45-54 55-64 65+ Total 
No. of TB patients          
No. of HIV+TB patients          
 
Type of TB cases and site of TB infection with HIV status 
 
Type of TB patient 
Site  of TB infection 
Total 
Pulmonary  Extra 
Pulmonary 
Other 
New 
Case 
Relapse Defaulter 
Not 
Specified 
Total  TB 
patient 
        
HIV Positive 
TB patient 
        
HIV Negative 
TB patient 
        
Not tested TB 
patient 
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